Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care

Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study

(2021) Richard M. Hoffman et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance

(2020) Mufaddal K. Mamawala et al.   BJU INTERNATIONAL

Five-year Outcomes of Magnetic Resonance Imaging–based Active Surveillance for Prostate Cancer: A Large Cohort Study

(2020) Vasilis Stavrinides et al.   EUROPEAN UROLOGY

Dermatofibrosarcoma Protuberans: Update on the Diagnosis and Treatment

(2020) Xingpei Hao et al.   Journal of Clinical Medicine

Genomic Markers in Prostate Cancer Decision Making

(2018) Vito Cucchiara et al.   EUROPEAN UROLOGY

Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance

(2018) Oudai Hassan et al.   JOURNAL OF UROLOGY

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options

(2018) Martin G. Sanda et al.   JOURNAL OF UROLOGY

Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer

(2018) H. Ballentine Carter et al.   EUROPEAN UROLOGY

Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer

(2017) Blake B. Anderson et al.   EUROPEAN UROLOGY

Racial Disparities in Active Surveillance for Prostate Cancer

(2017) Suprita Krishna et al.   JOURNAL OF UROLOGY

Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden

(2017) Stacy Loeb et al.   JAMA Oncology

A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score

(2016) Jonathan I. Epstein et al.   EUROPEAN UROLOGY

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience

(2016) Hima Bindu Musunuru et al.   JOURNAL OF UROLOGY

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

(2016) Freddie C. Hamdy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma

(2016) Yuri E. Nikiforov et al.   JAMA Oncology

Disease-specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy

(2015) Charlotte F. Kweldam et al.   BJU INTERNATIONAL

Trends in Management for Patients With Localized Prostate Cancer, 1990-2013

(2015) Matthew R. Cooperberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prognostic Gleason grade grouping: data based on the modified Gleason scoring system

(2013) Phillip M. Pierorazio et al.   BJU INTERNATIONAL

Punctuated Evolution of Prostate Cancer Genomes

(2013) Sylvan C. Baca et al.   CELL

Gleason 6 Prostate Tumors Diagnosed in the PSA Era Do Not Demonstrate the Capacity for Metastatic Spread at the Time of Radical Prostatectomy

(2013) Nicholas M. Donin et al.   UROLOGY

Do Adenocarcinomas of the Prostate With Gleason Score (GS)≤6 Have the Potential to Metastasize to Lymph Nodes?

(2012) Hillary M. Ross et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

(2012) A. Pettersson et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades

(2012) Jonathan I. Epstein et al.   EUROPEAN UROLOGY

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

(2012) Christopher E Barbieri et al.   NATURE GENETICS

Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience

(2011) Jeffrey J. Tosoian et al.   JOURNAL OF CLINICAL ONCOLOGY